By combining innovation in product development with competitive pricing, we work in partnership with healthcare professionals and patients to create real, long-term value, a major factor in our success to date.

We are a privately owned pharmaceutical company established in 1968, with headquarters in Craigavon, Northern Ireland.

Our expertise lies in

• sales, marketing and launch excellence
• market access
• regulatory affairs, pharmacovigilance and medical affairs
• supply chain and logistics.

We market pharmaceuticals across the UK, Europe, the USA and the Nordics.

Through organic growth and acquisitions, We have established product sales in 25 locations. 

We are a proud member of the Almac Group of world-class companies in the pharmaceutical and biotech sectors.  The Group is wholly owned by the McClay Foundation, whose overarching aim is to make a meaningful improvement and advancement in human health.

Galen was founded in Craigavon, Northern Ireland in 1968 by the late Sir Allen McClay (d. 2010), the revered philanthropist and entrepreneur.

Sir Allen invested his wealth in research and innovation, to ensure the latest advances in healthcare would be available to all, and to foster employment opportunities locally. In 1997, Galen became Northern Ireland’s first £1 billion company.

• In 2002, Sir Allen formed what is now known as the Almac Group from his personal wealth, whilst maintaining his controlling share of Galen.
• He later established the McClay Foundation as a charitable institution, donating more than £20 million to enhance the research capabilities at Queen’s University Belfast.
• Galen is proud member of the Almac Group of world-class companies in the pharmaceutical and biotech sectors. The Group is wholly owned by the McClay Foundation, whose overarching aim is to make a meaningful improvement and advancement in human health.

We champion the values upon which Galen was built, and remain passionate about Sir Allen’s mission to improve and optimise human health, and to achieve a meaningful impact on patients' lives.